Milena McLaughlin
Overview
Explore the profile of Milena McLaughlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McLaughlin M, Kalfayan N, Grant J, Hawkins C, Cottreau J, Palella Jr F, et al.
J Pharm Technol
. 2021 Dec;
34(4):149-152.
PMID: 34860986
The process of obtaining approval for hepatitis C virus (HCV) treatment may be time consuming and complicated due to prior authorizations and the need to appeal denials. Pharmacists are poised...
2.
Mathur S, Roberts-Toler C, Tassiopoulos K, Goodkin K, McLaughlin M, Bares S, et al.
J Acquir Immune Defic Syndr
. 2019 Jun;
82(1):88-95.
PMID: 31169770
Background: Mental health conditions are common among persons with HIV (PWH). An understanding of factors associated with prescription medication use for these conditions and clinical impact of the prescription medications...
3.
Rac H, Gould A, Eiland L, Griffin B, McLaughlin M, Stover K, et al.
Ann Pharmacother
. 2018 Dec;
53(6):639-651.
PMID: 30556401
Objective: To review the treatment of common bacterial and viral infections occurring in the pregnant patient. Data Sources: A literature search of MEDLINE was performed (inception to October 2018). The...
4.
McLaughlin M, Gordon L, Kleyn T, Lamsen M, Scott J
J Am Pharm Assoc (2003)
. 2018 Jan;
58(2):168-173.e3.
PMID: 29366696
Objectives: To ascertain the reasons for, benefits of, and barriers to pursuing the American Academy of HIV Medicine (AAHIVM) HIV Pharmacist (AAHIVP) credential. Methods: A cross-sectional study using an electronic...
5.
Copeland V, McLaughlin M, Trifilio S
Clin Transplant
. 2017 Oct;
32(1).
PMID: 29080369
The objective of the current retrospective study was to compare differences in rate of breakthrough infections for ciprofloxacin vs levofloxacin prophylaxis in autologous hematopoietic stem-cell transplant (HSCT) patients treated for...
6.
McLaughlin M, Walsh S, Galvin S
J Antimicrob Chemother
. 2017 Oct;
73(1):258-260.
PMID: 29077869
No abstract available.
7.
Watson L, Esterly J, Jensen A, Postelnick M, Aguirre A, McLaughlin M
J Glob Antimicrob Resist
. 2017 Oct;
12:104-106.
PMID: 28964955
Objectives: Stenotrophomonas maltophilia causes high mortality rates, especially in bloodstream infections (BSIs) where there is a lack of comparative data with fluoroquinolones (FQs) and sulfamethoxazole/trimethoprim (SXT). The objective of this...
8.
Bidell M, McLaughlin M, Faragon J, Morse C, Patel N
Infect Dis Ther
. 2016 Jul;
5(3):299-312.
PMID: 27384319
There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety...
9.
Hawkins C, Grant J, Ammerman L, Palella F, McLaughlin M, Green R, et al.
J Antimicrob Chemother
. 2016 Jun;
71(9):2642-5.
PMID: 27330060
Objectives: There are few data on the real-world experience of FDA-approved oral hepatitis C virus (HCV) direct-acting antiviral (DAA) drug combinations in HIV/HCV-coinfected patients. We evaluated the safety and efficacy...
10.
Lopez L, Rusconi B, Gildersleeve H, Qi C, McLaughlin M, Scheetz M, et al.
Genome Announc
. 2016 Mar;
4(2).
PMID: 26966211
Klebsiella pneumoniae is a nosocomial pathogen of emerging importance and displays resistance to broad-spectrum antibiotics, such as carbapenems. Here, we report the genome sequences of five clinical K. pneumoniae isolates,...